Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients

Blood

Volumn 69, Issue 6, 1987, Pages 1654-1660

  Ettinghausen, S E ^a   Moore, J G ^a   White, D E ^a   Platanias, L ^b   Young, N S ^b   Rosenberg, S A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOXEPIN; HYDROXYZINE; INDOMETACIN; PARACETAMOL; PETHIDINE; RANITIDINE; RECOMBINANT INTERLEUKIN 2;

ADVERSE DRUG REACTION; ANEMIA; BLOOD AND HEMOPOIETIC SYSTEM; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG THERAPY; EOSINOPHILIA; ERYTHROID PRECURSOR CELL; GRANULOCYTE PRECURSOR; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE PRECURSOR; PRIORITY JOURNAL; THERAPY; THROMBOCYTOPENIA;

EID: 0023189209     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v69.6.1654.1654     Document Type: Article

References (0)